Please ensure Javascript is enabled for purposes of website accessibility

2 Mid-Cap Biotech Stocks to Buy Right Now

By George Budwell - Jan 22, 2020 at 11:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.

Generally speaking, biotech stocks were one of the best places to put your money in 2019. The iShares Nasdaq Biotechnology ETF gained a stellar 25.2% last year, despite the political wrangling over prescription drug prices in the United States. Fortunately, this upward trend should continue unabated in 2020. The biotech industry, after all, has been generating game-changing breakthroughs across a number of areas in recent years, opening up a wide range of novel, high-value markets.

Where should cautious investors put their money in the diverse landscape that is biotech? Mid-cap biotechs -- or companies with market caps of between $2 billion to $10 billion -- tend to offer a compelling mix of upside potential and relative safety for individuals that like to avoid hefty doses of risk. The fundamental reason is that biotechs with modest market caps generally have at least one approved product on the market, stable and growing free cash flows, and assets that may attract a larger partner. 

A businessman holding a set of large yellow blocks that spell out the word "buy" in red capital letters.

Image source: Getty Images.

Which mid-cap biotechs are worth buying right now? Amarin (AMRN 19.20%) and Intercept Pharmaceuticals (ICPT 2.52%) are two names worth checking out during the early days of 2020. Here's why. 

Amarin: All systems are go

Late last year, the U.S. Food and Drug Administration (FDA) granted Amarin's supplemental New Drug Application to expand the label of its highly refined omega-3 treatment known as Vascepa. This broader label is widely expected to grow the drug's target market exponentially in the coming years. What this means is that Vascepa has a real shot at achieving blockbuster status (greater than $1 billion in annual sales) perhaps as soon as 2021, and maybe even megablockbuster status (greater than $5 billion in annual sales) in the latter half of the decade. Amarin's stock, in kind, should benefit tremendously from this sizable commercial opportunity. 

Not all Wall Street analysts are sold on Amarin's prospects, however. Even though AstraZeneca recently bowed out of the omega-3 treatment game and Acasti Pharma's rival therapy, CaPre, flamed out in late-stage testing, Amarin still has its fair share of skeptics on Wall Street. Oppenheimer's Leland Gershell, for example, has argued that the biotech's shares are grossly overvalued at current levels due to the enormous costs associated with launching a novel medication into a large market.

While Amarin's detractors may be proven correct in the final analysis, the facts on the ground clearly favor the bull thesis for Vascepa. The drug has no equal from an efficacy standpoint, it's relatively cheap for a branded prescription medication, and millions of Americans need an add-on to statin therapy to control their triglyceride levels. So even though it may take a while for Vascepa to truly benefit from this recent label expansion, there's no logical reason to believe that it won't ultimately become a smashing commercial success. As a result, this mid-cap biotech stock should appeal to most investors on the hunt for healthy growth opportunities.   

Intercept: A unique buying opportunity

Intercept is on the cusp of a truly staggering commercial opportunity. Last year, the biotech became the first ever to generate positive top-line data in a late-stage trial targeting non-alcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that currently has no approved treatments. Intercept's NASH candidate is Ocaliva, a drug already approved for another serious liver disease known as primary biliary cholangitis. Last September, the biotech filed a regulatory application with the FDA for Ocaliva's NASH indication. The agency's regulatory decision is currently slated for mid-2020. If things go according to plan, Intercept plans to begin marketing Ocaliva as a ground-breaking NASH treatment by the middle of 2020.

What's the big deal? NASH may be the largest untapped commercial opportunity in all of biopharma. Due to the out-of-control obesity epidemic in many Western countries, industry insiders have suggested that NASH drug sales could one day exceed a jaw-dropping $60 billion per year. That's not quite on par with oncology, but it is a staggering figure nonetheless. Ocaliva, as the first approved NASH medication, should thus have no problem hitting at least $2 billion in annual sales. That's a hefty commercial opportunity for a company with a market cap of $3.3 billion right now.

What's the risk? Ocaliva does have some worrying side effects that could prove problematic during the current review cycle. That being said, Ocaliva has so far been the only NASH drug candidate to meet a key primary endpoint in a pivotal stage trial. Moreover, there is a well-documented need for some form of viable treatment option for this deadly liver ailment. So the odds are that regulators will indeed approve Ocaliva, but perhaps with a restrictive label. Regardless, an approval for NASH -- even one with a black-box warning label -- should be worth several billion in annual sales. That's arguably reason enough to have this mid-cap biotech on your radar right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.49 (19.20%) $0.24
Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$17.88 (2.52%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.